Acceleron Pharma Inc. (NASDAQ:XLRN)‘s stock had its “hold” rating reiterated by equities researchers at Royal Bank Of Canada in a note issued to investors on Thursday, November 2nd.
Several other research analysts have also weighed in on the stock. HC Wainwright began coverage on shares of Acceleron Pharma in a research note on Thursday, October 12th. They issued a “buy” rating and a $57.00 price objective on the stock. ValuEngine downgraded shares of Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Acceleron Pharma in a report on Wednesday, September 20th. Barclays PLC increased their price objective on shares of Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, September 20th. Finally, UBS AG reaffirmed a “buy” rating and issued a $50.00 target price (up previously from $36.00) on shares of Acceleron Pharma in a research note on Tuesday, September 12th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $44.88.
Shares of Acceleron Pharma (NASDAQ XLRN) opened at $34.12 on Thursday. Acceleron Pharma has a one year low of $23.07 and a one year high of $41.69.
Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.52 million. During the same period in the prior year, the business earned ($0.55) earnings per share. The business’s quarterly revenue was up .0% on a year-over-year basis. research analysts predict that Acceleron Pharma will post -2.67 earnings per share for the current fiscal year.
WARNING: This report was published by BBNS and is owned by of BBNS. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://baseballnewssource.com/markets/royal-bank-of-canada-reiterates-hold-rating-for-acceleron-pharma-inc-xlrn/1751024.html.
In related news, SVP John D. Quisel sold 5,113 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $38.42, for a total value of $196,441.46. Following the completion of the sale, the senior vice president now directly owns 57,918 shares of the company’s stock, valued at approximately $2,225,209.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Corp /De/ Celgene bought 745,592 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were acquired at an average cost of $37.00 per share, with a total value of $27,586,904.00. Following the completion of the transaction, the insider now owns 6,118,479 shares in the company, valued at $226,383,723. The disclosure for this purchase can be found here. Insiders have sold a total of 53,513 shares of company stock valued at $2,055,485 in the last three months. Insiders own 3.90% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP increased its holdings in Acceleron Pharma by 416.3% in the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 2,352 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in Acceleron Pharma by 969.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 3,288 shares during the last quarter. NJ State Employees Deferred Compensation Plan purchased a new stake in Acceleron Pharma in the 2nd quarter worth about $213,000. Oppenheimer & Co. Inc. purchased a new stake in Acceleron Pharma in the 3rd quarter worth about $225,000. Finally, Tudor Investment Corp ET AL increased its holdings in Acceleron Pharma by 8.5% in the 1st quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 716 shares during the last quarter. 75.85% of the stock is owned by hedge funds and other institutional investors.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with our FREE daily email newsletter.